Mechanistic insights into synergistic effects using coupled PK-PD modeling

Area of Science:

• Pharmacology
• Pharmacokinetics
• Pharmacodynamics
• Neuroscience

Background:

• Ischemic stroke is a leading cause of disability and mortality.
• Hydroxysafflor Yellow A (HSYA) and Calycosin (CA) are potential therapeutic agents for ischemic stroke.
• Quantitative evaluation of their combined effects is crucial for optimizing treatment.

Purpose of the Study:

• To develop and apply a novel coupled pharmacokinetic-pharmacodynamic (PK-PD) model.
• To quantitatively evaluate the synergistic effects of HSYA and CA in ischemic stroke treatment.
• To reveal the interaction mechanisms between HSYA and CA.

Main Methods:

• A middle cerebral artery occlusion (MCAA) rat model was used.
• Plasma drug concentrations were analyzed using LC-MS.
• Pharmacodynamic markers (Caspase-9, IL-1β, SOD) were measured by ELISA.
• A coupled PK-PD model with interaction terms was developed and numerically solved.

Main Results:

• HSYA and CA increased each other's metabolic rates.
• CA exhibited a larger volume of distribution and clearance; HSYA had a shorter retention time and half-life.
• The coupled PK-PD model demonstrated synergistic effects of HSYA and CA on all measured pharmacodynamic markers, with HSYA showing a more significant contribution.

Conclusions:

• The developed coupled PK-PD model successfully quantified the synergistic effects of HSYA and CA in ischemic stroke.
• The model provides a foundation for future research on complex drug interactions and effects.
• This approach can guide the development of optimized combination therapies for ischemic stroke.